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Abstract
Objective
New guidelines recommend that all HIV-infected individuals initiate antiretroviral treatment
(ART) immediately following diagnosis. This study describes how immune reconstitution
varies by gender and age to help identify poorly reconstituting subgroups and inform tar-
geted testing initiatives.
Design
Longitudinal data from the outpatient monitoring system of the National AIDS Control Pro-
gram in Tanzania.
Methods
An asymptotic nonlinear mixed effects model was fit to post-treatment CD4+ cell count tra-
jectories, allowing for fixed effects of age and sex, and an age by sex interaction.
Results
Across 220,544 clinic visits from 32,069 HIV-infected patients, age- and sex-specific aver-
age CD4+ cell count at ART initiation ranged from 83–136 cells/mm3, long term asymptotic
CD4+ cell count ranged from 301–389 cells/mm3, and time to half of maximal CD4+ recon-
stitution ranged from 3.57–5.68 months. CD4+ cell count at ART initiation and asymptotic
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CD4+ cell count were 1.28 (95% CI: 1.18–1.40) and 1.25 (95% CI: 1.20–1.31) times higher,
respectively, for females compared to males in the youngest age group (19–29 years).
Older patients started treatment at higher CD4+ counts but experienced slower CD4+
recovery than younger adults. Treatment initiation at greater CD4+ cell counts was corre-
lated with greater asymptotic CD4+ cell counts within all sex and age groups.
Conclusion
Older adults should initiate care early in disease progression because total immune recon-
stitution potential and rate of reconstitution appears to decrease with age. Targeted HIV
testing and care linkage remains crucial for patient populations who tend to initiate treat-
ment at lower CD4+ cell counts, including males and younger adults.
Introduction
In 2013, 24.7 million (23.5–26.1 million) people were estimated to be living with HIV in sub-
Saharan Africa and 37% of those living with HIV were receiving antiretroviral therapy (ART)
[1]. In Tanzania, over 1.5 million people are estimated to be infected with HIV, 41% of whom
were estimated to have initiated treatment as of 2013 [1, 2]. It is important for HIV-infected
individuals to initiate ART in order to improve immune function, slow disease progression [3],
decrease risk of HIV transmission [4], and reduce risk of AIDS-associatedmortality [5]. These
and other benefits associated with ART are in part realized through reductions in HIV viral
load and increases in CD4+ T white blood cell counts.
CD4+ cell count has historically been used to guide clinical decisionmaking regarding ART
initiation, regimen switching, and clinical monitoring [6]. The most recent 2015 World Health
Organization (WHO) treatment guidelines recommend treatment for all HIV-infected individ-
uals regardless of CD4+ cell count [7]. During the period spanning the data analyzed here
(2003–2012), Tanzanian treatment guidelines recommended treatment initiation at CD4+ cell
counts below 200 cells/mm3, below CD4+ cell counts of 350 cells/mm3 for individuals in WHO
Stage 3, and for all individuals meetingWHO Stage 4 clinical criteria regardless of CD4+ cell
count [6].
HIV utilizes and destroys CD4+ cells during viral replication and thus CD4+ cell counts are
one clinical indicator of immune function or reconstitution following treatment initiation.
Reductions in CD4+ cells and the resulting inflammation and immunosuppression are associ-
ated with onset of multiple co-morbid opportunistic infections such as tuberculosis, candidia-
sis, pneumonia, Kaposi’s sarcoma, and other conditions [8, 9]. However, different
opportunistic infections occur at varying levels of CD4+ depletion and immune function [10].
Thus, it is important to understand how CD4+ levels change after treatment initiation in order
to understand the changing clinical vulnerabilities of a patient throughout immune
reconstitution.
Baseline CD4+ cell counts tend to vary by country; a cross-sectional study in Zimbabwe and
Uganda found that among both HIV-uninfected and HIV-infected women, CD4+ cell counts
were lower in Zimbabwe than Uganda, after controlling for age, contraceptive method, educa-
tion, and partner HIV status [11]. However, CD4+ levels also vary within populations and,
importantly, CD4+ cell reconstitution following ART initiation may differ by age and sex [10,
12–14].
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Once an individual begins treatment CD4+ cell counts generally increase at a constant rate
before plateauing [15]. Initial rapid increases in CD4+ cell levels following ART initiation are
likely associated with the redistribution of cells stored in the lymphoreticular system [16]. The
less rapid increase in cells that follows (i.e. plateauing) is due in part to the generation of naïve
CD4+ cells through cell division or from the thymus [17].
Due to the combination of within-individual variability (such as diurnal variation) and
measurement error variability (i.e. imperfect instruments), capturing the trends in CD4+ cell
count trajectory is challenging.While a number of studies have simply presented descriptive
statistics (i.e. mean, median) at time points following ART initiation[18–20], this fails to take
into account the longitudinal nature of CD4+ cell count trajectories. Several modeling strate-
gies have been utilized to more rigorously describeCD4+ cell count recovery trajectories fol-
lowing ART initiation. Some have used linear mixed effectsmodels[21–24], which have the
drawback of enforcing a linear trend on every individual’s CD4+ cell count trajectory. Addi-
tional linear models include spline terms to account for changing slope over time[15, 25],
including hierarchical Bayesian change-point models[26]. Somemodels incorporate smooth-
ing terms [27, 28] or latent trajectory fitting[24], which incorporates additional flexibility but
simultaneously limits interpretability of the model terms. Other studies have used three
parameter asymptotic nonlinear mixed effectsmodels, which allow for nonlinear CD4+ cell
count trajectories [29–31].
Due to the influence of CD4+ cell counts on long term patient outcomes, it is important to
understand the impact of baseline CD4+ cell counts and other patient characteristics on long-
term immune recovery. Leveraging a Tanzanian national HIV patient data base, this study
describes the correlation between patient-level baseline and long-term immune CD4+ cell
counts and to identify demographic factors mediating this correlation.
Methods
Study design
We analyze longitudinal clinical data from the outpatient monitoring system of the National
AIDS Control Program (NACP) in Tanzania. The system utilizes sets of recording and report-
ing tools and is distinctively centralized, with a national database that recognizes each patient
by their unique Care and Treatment Clinic (CTC) ID number from all over the country. All
individuals enrolled in care are supplied with client held CTC-1 cards. Elementary records of
patient encounters are captured within facility-held CTC-2 cards, which are the foundation of
both the paper and electronic systems currently in use.
Study participants
Our study population includes treatment and morbidity characteristics of HIV-infected adults
receiving treatment between 2003 and 2012 at CTCs in three provinces: Mwanza, Dar es Salam
and Tanga. We restricted the analysis to individuals 19 years of age or older at ART initiation
who had complete patient records that included: patient sex, ART initiation date, age at ART
initiation, baseline CD4+ cell count (within 2 months prior or 3 months post-treatment initia-
tion), and five or more documented visits at which CD4+ cell count was measured (excluding
visits more than 2 months prior to ART initiation). The data were de-identified and anon-
ymized prior to data analysis. The Ministry of Health and SocialWelfare routinely collects this
de-identified, anonymous surveillance data. We received approval to conduct these analyses
from the Tanzanian National AIDS Control Programme, and a waiver for ethical review from
the Johns Hopkins Bloomberg School of Public Health.
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Statistical analysis
We used a hierarchical nonlinear mixed effects (NLME)model to fit CD4+ cell count progres-
sion following ART initiation. The model’s fixed effects describe the population average
response while the random effects describe patients’ deviation from the population average
within a given fixed effect category (i.e. between subject variability).
We used a negative exponential asymptotic function as the basis of the NLMEmodel (Fig
1). Consistent with previous studies of CD4+ cell trajectories, this approach assumes asymp-
totic behavior for long-term CD4+ cell recovery [29–31]. A recent study of CD4+ cell recovery
in pediatric patients found that fits of this asymptotic model did not converge for all patients
and, consequently, assumed that lack of convergence indicated that the asymptotic model was
an inadequate representation of those patient trajectories. These authors chose to fit linear
mixed effectsmodels to those patients instead [32]. However, we expand from this work by
noting that lack of convergence when fitting a model indicates only uncertainty that the fitting
algorithm identified the best estimates of the model parameters; it does not indicate that the
model is an inadequate fit. Lack of convergence is more likely to occur when fitting more com-
plicated models to data that are noisy or sparse (e.g. linear models are simple enough to always
converge given at least two observationswhereas asymptotic models may not easily converge
for small numbers of observations particularly when they are noisy around the asymptotic
trend).
We explored these alternatives by simulation. We took the best-fit parameters from our best
asymptotic nonlinear mixed model and used that model to simulate patient data. Because these
data were simulated from a truly asymptotic model, with observation-level noise and inter-
patient variation representative of the real data, they provide a rigorous test case to identify
whether lack of convergence of an asymptotic model indeed indicates a poormodel or whether
Fig 1. Asymptotic model diagram. Schematic diagram of the negative exponential asymptotic model of CD4+
cell recovery. Int, Asym and the half life (t50%) represent the CD4+ cell count at initiation of antiretroviral treatment,
the asymptotic CD4+ cell count and the time to reach 50% of the maximal CD4+ recovery, respectively.
doi:10.1371/journal.pone.0164148.g001
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instead that lack of convergence could be a symptom of fitting a complicated model to noisy
and sparse data. Indeed, we found that the asymptotic model did not converge for 38.5% of
simulated (and truly asymptotic) patient trajectories. In contrast, only 18% of data from real
patients failed to converge. We thus conclude that failed convergence is not sufficient cause to
reject an underlying asymptotic model for patients within our data set and, consequently, ana-
lyzed all patients using an asymptotic CD4+ cell recoverymodel.We further highlight that
asymptotic models are fairly flexible three parameter models that can yield approximately lin-
ear trajectories such that dividing patients into those for whom it’s easier to fit a linear model
versus an asymptotic model is unnecessary.
The asymptotic function used is such that given individual j, the logarithm of CD4+ cell
count at time tij is modelled as
logðCD4ijÞ ¼ Asymj   ðAsymj   IntjÞexpð  cjtijÞ þ εij ð1Þ
whereAsymj, Intj and cj are patient j specific parameters, tij is the time of follow up in years and
εi,j is the error term.
The parameters in the NLMEmodel represent individual-level biological processes: the
intercept Intj is the logarithm of the CD4+ cell count at ART initiation for patient j, the asymp-
tote Asymj is the logarithm of the long-term reconstituted CD4+ cell count, and cj is the rate of
exponential decay from the initial log CD4+ cell count upwards to the asymptotic log CD4+
cell count (decay is upwards in the negative exponential asymptotic model). This parameter
can be more intuitively understood by considering the half-life, which is the time needed to
reach 50% of the total CD4+ cells increase, t50% = −ln(0.5)/c, or to reach 90% of the total
increase, t90% = −ln(0.1)/c. The error term εi,j is assumed to be normally distributed and repre-
sents variation due to CD4+ cell count measurement error or due to a patient’s day-to-day var-
iation around their average CD4+ cell count trajectory. In order to simplify the results,
estimated parameters were exponentiated so that they could be interpreted on a CD4+ cell
(and not log(CD4+)) scale.
In our hierarchical asymptotic model, we used Akaike information criterion (AIC) model
selection to determine whether to include the effects of sex, age categories, or a sex by age inter-
action on each of the three asymptotic model parameters (asymptotic CD4+ cell count, CD4+
cell count at ART initiation, and the log rate of CD4+ cell increase), yielding four possible com-
binations (intercept only, sex only, age only, sex by age interaction) for each asymptotic model
parameter. We then considered all 64 possible combinations (43) of these fixed effects for the
three asymptotic model parameters. In all models, we also specified that each of the three
asymptotic model parameters have a patient-level random effect, with these random effects’
correlations estimated from the data (e.g. patients with lower initial CD4+ cell counts may
have lower final CD4+ cell counts, on average, than the average patient within their age-sex
strata). A single model was clearly distinguishable as the best model (no other models were
within 2 ΔAIC of the best model), and we only present results for this single model. This model
included age-by-sex interactions for initial and asymptotic CD4+ count, but only an effect of
age on the rate parameter:
Intj ¼ b
Int
j;sex;age þ εj;Int ð2Þ
Asymj ¼ b
Asym
j;sex;age þ εj;Asym ð3Þ
logðcjÞ ¼ b
Asym
j;age þ εj;c ð4Þ
Impact of Age and Sex on CD4+ Cell Count
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where bIntj;sex;age, for example, denotes that effect of being in individual j’s age and sex category on
the initial log CD4+ count and εj,Int indicates that individual’s initial log CD4+ count’s random
deviation from other individuals in the same age and sex group, with the three random effect
terms beingmultivariate normally distributed. Confidence intervals for all parameters of inter-
est were constructed based on linear combinations of fitted coefficients using their variance
covariance matrix and the corresponding variance transformations. All analysis was performed
in the statistical environment R (available at: http://www.r-project.org) using the nlme package
for nonlinear modeling [33].
Results
The patient sample analyzed included 220,544 clinic visits from 32,069 HIV-infected patients
(Table A in S1 File shows patient exclusion criteria). At baseline, the largest proportion of
patients were aged 30–39 while the smallest proportion of patients occurred in the>60 age
group. The median CD4+ cell count was 135 (IQR 64–209) and nearly half of patients were
classified as WHO Stage 3. Older patients were more likely to initiate treatment at higher CD4+
cell counts and later WHO stages than younger age groups. Over the duration of visits (ranging
fromOctober 2003 to September 2012), the mean number of patient visits was 6.9 and patients
were followed for a median of 3.7 (IQR 2.8–4.7) years (Table 1 and Table B in S1 File).
Nearly three quarters (70.4%) of patients were female. Male patients were most common in
the lowest CD4+ strata (0–50 CD4+ cells/mm3) at 34.0% and oldest age groups (61+) at 48.6%.
Male patients were least common in the highest CD4+ strata (>500 CD4+ cells/mm3) at 22.9%
and youngest age groups (19–30) at 13% (Table C in S1 File). Very few (3.3%) females were
pregnant at ART initiation (Table 1).
Using AIC, our best fit model included an age by sex interaction term for the initial and
asymptotic log CD4+ cell counts, and age for the CD4+ cell rate of increase parameter
(Table D in S1 File).
CD4+ cell counts at ART initiation by age and gender
The estimated average CD4+ cell count at ART initiation was 83.4 cells/mm3 among 19–29
year old males and increased steadily with age to 121 cells/mm3 for>60 year old men, equating
to a 1.45-fold (1.26–1.66) differences between these age groups (Fig 2, Tables E and F in S1
File). Within the youngest age group, CD4+ cell count at ART initiation was 107 cells/mm3, i.e.
1.28 (95% CI: 1.18–1.40) times higher for females compared to men. CD4+ cell count at ART
initiation amongst female patients also increased steadily with age, though this trend was less
pronounced, with>60 year old females exhibiting an average of 136 cells/mm3.
Asymptotic CD4+ cell counts by age and gender
The estimated average asymptotic CD4+ cell count (reflecting long-term CD4+ cell recovery)
for males aged 19–29 was 301 CD4+ cells/mm3. Females in the 19–29 year age group had a
1.25 times greater asymptotic CD4+ cell count relative to males of the same age at 377 cells/
mm3. Asymptotic CD4+ cell count only varied slightly by age group with 30–49 year old males
exhibiting the greatest value amongst males at 323 cells/mm3, and 51–60 year old females
exhibiting the greatest amongst females at 389 cells/mm3.
Rate of CD4+ cell recovery by age
The rate of CD4+ cell recovery as measured by time until 50% of maximal CD4+ recovery
reached was similar between sexes but slower with increasing age with an estimated 3.72
Impact of Age and Sex on CD4+ Cell Count
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months and 4.99 months until 50% recovery for 19–29 year olds and>60 year old individuals,
respectively. When measured as time until a 50 cells/mm3 increase since treatment initiation
(which accounts for the different amount of CD4+ cells gained across age-sex groups), females
recovered more quickly than males and older ages recovered more slowly in both sexes, with
19–29 year old males and females taking 1.4 and 1.1 months, respectively, and>60 males and
females taking 2.26 and 1.78 months, respectively, to gain 50 cells/mm3.
Individual variability within age-sex groups
The standard deviation of clinic observation-level residuals (e.g. εij) was 0.58. As characterized
by the fitted patient-level random effects, we observed substantial variation between patients in
their log CD4+ cell counts at ART initiation (standard deviation, SD: 0.90), their asymptotic
log CD4+ cell counts (SD: 0.51), and their log rate of CD4+ cell increase (SD: 0.74). We addi-
tionally observed a strong positive correlation between patient-level random effects for initial
and asymptotic CD4+ cell counts (correlation on log CD4+ scale: 0.40, 95% CI: 0.39–0.42),
such that individuals with a greater CD4+ cell count at ART initiation exhibited a greater long
term CD4+ cell count. Notably, this correlation remained consistent when examining patient-
level correlations within age-sex groups (Fig 3). We observed a strong positive correlation
between amount of CD4+ cells gained (i.e. difference between initial and asymptotic values)
and the time taken to recover as measured by the time taken to attain 50% of the maximal
CD4+ cells gained (Figure A in S1 File; correlation betweenAsym and log(c) estimated as -0.60,
95% CI: -0.62 to -0.58). Finally, there was no notable correlation between the CD4+ cell count
at ART initiation and the number of CD4+ cells gained (Figure B in S1 File).
Discussion
NewWHO guidelines recommend that all HIV-infected individuals should initiate ART fol-
lowing an HIV diagnosis [7]. However, clinical decisions to initiate or change treatment may
Table 1. Demographic characteristics and follow-up data of analyzed patients.
Age group 19–29 30–39 40–49 50–59 >60 all
Number of patients 5155 (100%) 13927 (100%) 9038 (100%) 3152 (100%) 797 (100%) 32069 (100%)
Number of visits 35222 96139 62454 21504 5225 220544
Average visits/patient 6.8 6.9 6.9 6.8 6.6 6.9
Median follow-up time per patient (years) 3.6 3.7 3.7 3.7 3.5 3.7
Number of female patients 4487 (87%) 10344 (74.3%) 5601 (62%) 1732 (54.9%) 410 (51.4%) 22574 (70.4%)
Number pregnant (% amongst female patients) 307 (6.84%) 366 (3.54%) 28 (0.5%) 3 (0.17%) 2 (0.49%) 706 (3.13%)
Baseline CD4+ count (% within age group)
0–50 1189 (23.1%) 2964 (21.3%) 1706 (18.9%) 522 (16.6%) 114 (14.3%) 6495 (20.3%)
51–200 2512 (48.7%) 7336 (52.7%) 4894 (54.1%) 1700 (53.9%) 434 (54.5%) 16876 (52.6%)
201–350 1093 (21.2%) 2789 (20%) 1865 (20.6%) 720 (22.8%) 183 (23%) 6650 (20.7%)
351–500 208 (4.03%) 503 (3.61%) 367 (4.06%) 139 (4.41%) 45 (5.65%) 1262 (3.94%)
500+ 153 (2.97%) 335 (2.41%) 206 (2.28%) 71 (2.25%) 21 (2.63%) 786 (2.45%)
WHO stage (% within age group)
1 644 (12.5%) 1480 (10.6%) 749 (8.29%) 286 (9.07%) 59 (7.4%) 3218 (10%)
2 1026 (19.9%) 2727 (19.6%) 1722 (19.1%) 621 (19.7%) 142 (17.8%) 6238 (19.5%)
3 1914 (37.1%) 5393 (38.7%) 3642 (40.3%) 1268 (40.2%) 331 (41.5%) 12548 (39.1%)
4 559 (10.8%) 1617 (11.6%) 1116 (12.3%) 368 (11.7%) 108 (13.6%) 3768 (11.7%)
Unknown 1012 (19.6%) 2710 (19.5%) 1809 (20%) 609 (19.3%) 157 (19.7%) 6297 (19.6%)
doi:10.1371/journal.pone.0164148.t001
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continue to be made at an individual level for the immediate future due to a dearth of medica-
tion in low-resource settings and in accordance with country-specificguidelines. This analysis
identifies demographic factors underlying patient-level variation in CD4+ cell count trajecto-
ries, using an asymptotic nonlinear mixed model, which not only takes into account the
asymptotic behavior of long term CD4+ cell counts but also quantifies the between subject var-
iability in the initial and asymptotic CD4+ cell counts as well as the rate of recovery.
In this study, females tended to have higher CD4+ cell counts at ART initiation. This find-
ing is consistent with previous research, includingMalaza et al., a recent population-based
study in Kwazulu-Natal, South Africa, which found that HIV-negative females had higher
CD4+ cell counts than males [34]. Additionally, females in this study tended to achieve a
greater CD4+ reconstitution than males (on average between 51–76 cells/mm3 higher).
Fig 2. Estimated effects of age and sex on CD4+ cell count response to treatment. Points reflect fixed
effects parameters estimated from a hierarchical asymptotic nonlinear mixed effects model with error bars
indicating 95% confidence intervals. Numerical values given in Table C in S1 File.
doi:10.1371/journal.pone.0164148.g002
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Another study from South Africa found that females experiencedgreater CD4+ cell count
increases than males over the 36 months following ART initiation [12]. Evidence also suggests
that males experience greater virological failure and mortality rates relative to females after
starting treatment, likely due to delayed treatment initiation [35].
We also found that CD4+ cell count at ART initiation increased strongly with patient age at
ART initiation for both males and women. This contrasts with Malaza et al.’s population-based
study, which found that CD4+ cell counts increased slightly with age in HIV-uninfected indi-
viduals but indicated no consistent age pattern in HIV-infected individuals [34]. Thus, it
appears that in Tanzania, older individuals may seek care or, once in care, be initiated on ART
earlier in their disease course than younger individuals. This may also be partly explained by
older individuals progressing to later disease stages at greater CD4+ cell counts and, conse-
quently, meeting treatment threshold criteria at greater CD4+ cell counts than younger indi-
viduals. However, despite starting treatment at greater CD4+ levels older age groups did not
reach a higher CD4+ recovery asymptote relative to younger age groups. Additionally, older
individuals recovered more slowly than younger individuals whethermeasured as the time
taken to attain 50% of their maximal recovery or as time taken to increase 50 CD4+ cells/mm3
above their baseline level at treatment initiation. Thus, while older individuals initiate ART at
greater CD4+ counts, they appear to recover CD4+ cells at a slower rate and ultimately reach a
CD4+ cell count that is no higher than younger individuals. This is may be due to more rapid
disease progression [36, 37] and a decrease in the adaptive immune system activity of older
adults [38, 39], which may decrease the speed of CD4+ cell recovery.
Fig 3. Initial CD4+ cell count and asymptotic CD4+ cell count by age and sex. For each sex and age grouping, these panels
show estimated asymptotic CD4+ count versus estimated CD4+ count at treatment initiation, as fitted in the best fit asymptotic non-
linear mixed effects regression model of CD4+ counts over time for patients within the outpatient monitoring system of the National
AIDS Control Program in Tanzania. Each circle represents one patient. Blue lines show fitted linear regressions with value in bottom
right of each panel showing the R2 for this correlation.
doi:10.1371/journal.pone.0164148.g003
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We observed a positive correlation between patient-level CD4+ cell counts at ART initiation
and asymptotic CD4+ cell counts even after accounting for age and sex effects, indicating that
individuals who initiate treatment earlier in their disease course (before CD4+ cell count has
dramatically decreased) ultimately achieve a higher CD4+ cell count. We did not find any cor-
relation between patient-level CD4+ cell counts at ART initiation and the level of CD4+ cells/
mm3 gained, indicating that the benefits of starting early are due primarily to lower levels of
CD4+ depletion and not greater levels of CD4+ cells gained. Similarly, a study from the United
States found that after six years of ART, only patients with CD4+ cell counts of at least 350
cells/mm3 at baseline returned to near normal CD4+ levels [40]. These findings were recently
corroborated in cohorts in the United States and in Brazil; the weighted CD4+ cell counts of
3116 patients increased for four years following treatment before leveling off, however only
50% of the population attained CD4+ cell counts of at least 449 cells/mm3. The individuals
with pre-treatment CD4+ cell counts of at least 350 cells/ mm3 exhibited increasing CD4+ cell
counts over time with 76% of these patients exceeding the CD4+ cell count threshold of more
than 500 cells/mm3 ten years following ART initiation [18]. This finding is also consistent with
findings from a recent study of pediatricHIV patients which associated lower pre-ART CD4+
cell counts with lower long-term CD4+ cell counts [29]. Importantly, we found that the corre-
lation between initial and asymptotic CD4+ count remained consistent across age-sex groups,
implying that early ART initiation is beneficial for all sexes and ages.
This study has several limitations. First, selection bias could result from the individuals
excluded from our analytic dataset (those with less than 5 clinic visits) being substantially dif-
ferent than the individuals included. Additionally, due to incomplete patient records we were
not able to adjust for patient-level ART adherence or regimen.
Our findings suggest that across patients, earlier ART initiation is associated with greater
long term CD4+ cell counts. The importance of older adults initiating care early in their disease
progression is emphasized by the finding that their immune reconstitution rates are not as
high as younger patients. However older patients who start treatment earlier have improved
CD4+ trajectories relative to older patients who initiate treatment later. This study also high-
lights the importance of targeted HIV testing and linkage to care for patient populations who
appear to initiate treatment at lower CD4+ cell counts, including males and younger adults.
Because younger adults likely contribute substantively to sexual transmission of HIV it is
important for these populations to initiate therapy in order to reduce viral load and thus popu-
lation-level HIV transmission. Younger populations also experience rapid recovery once initi-
ated on therapy, which is important for long-term household livelihood,wellbeing, and
community development.
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